Pharmacogenomics Research Data: Governance and Analysis

Pharmacogenomics research data links genetic variation to how people respond to medicines, combining genotypes for drug-metabolizing genes with prescribing, dosing, and outcome records. Governing it well means treating it as both genetic and clinical data, with clear consent terms, controlled access, and strict output review, and the most effective way to analyze it across hospitals, biobanks, and trial sponsors is federated analysis: star-allele calling and outcome models run inside each custodian’s environment, and only aggregate results leave. That approach lets pharma sponsors test gene and drug associations across diverse populations without transferring any patient’s genome.

Why pharmacogenomics data governance matters now

Pharmacogenomics has moved steadily into routine care and drug development. The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed guidelines translating genotypes into prescribing actions for gene and drug pairs such as CYP2C19 and clopidogrel, CYP2D6 and codeine, TPMT and NUDT15 with thiopurines, and SLCO1B1 with simvastatin. The Dutch Pharmacogenetics Working Group (DPWG) publishes parallel guidance. The US Food and Drug Administration maintains a public table of pharmacogenomic biomarkers in drug labeling, and in 2020 the European Medicines Agency recommended testing for dihydropyrimidine dehydrogenase (DPD) deficiency before treatment with fluorouracil and related medicines.

For sponsors, this creates both opportunity and obligation. Genetic variation that affects drug exposure or safety can shape dose selection, trial enrichment, labeling, and post-marketing studies. Finding that variation needs large, diverse datasets that link genotype to real prescribing and outcomes. Those datasets sit in national genomics programs, hospital biobanks, and health systems that are bound by the General Data Protection Regulation (GDPR), national genomic laws, and consent terms that rarely allow data to be exported to a commercial partner.

Diversity makes the problem sharper. Allele frequencies for key pharmacogenes vary widely between populations. HLA-B*15:02, associated with severe skin reactions to carbamazepine, is far more common in parts of Southeast and East Asia than in Europe, which is why regulators in several countries recommend testing before treatment. A study that pools only European-ancestry cohorts will miss signals that matter for a global label.

What makes pharmacogenomics data different

It is genetic data with clinical consequences

Pharmacogenomic genotypes are special category data under GDPR and can reveal information about relatives. In the United States, the Genetic Information Nondiscrimination Act (GINA) restricts some uses of genetic information in health insurance and employment. Governance must reflect both the genetic sensitivity and the clinical meaning of the data.

It depends on complex genotype interpretation

Pharmacogenes are described with star-allele nomenclature curated by the Pharmacogene Variation Consortium (PharmVar). Converting raw genotypes into star alleles, diplotypes, and metabolizer phenotypes requires specialist tools such as PharmCAT, Aldy, or Stargazer. CYP2D6 is especially difficult because of gene deletions, duplications, and hybrid genes that short-read sequencing and genotyping arrays capture incompletely.

It needs rich medication data

A genotype is useful only when linked to what was prescribed, at what dose, for how long, and what happened next. Medication data must be harmonized to standard vocabularies, such as RxNorm or ATC codes within the OMOP Common Data Model, before analyses can run consistently across sites.

The Federated TRE angle for pharmacogenomics

A federated Trusted Research Environment (TRE) fits pharmacogenomics because the difficult, sensitive steps are local by nature. Each custodian already holds genotypes, prescribing records, and outcomes. In a Federated TRE, a sponsor’s approved analysis is sent to each custodian as a versioned, containerized workflow. Star-allele calling, phenotype assignment, and association or dose-response models run locally. At no point does the sponsor see a genome: data never leaves the source, and each aggregate output passes an automated airlock with statistical disclosure control before release.

This design answers the governance questions that stall most pharmacogenomics collaborations. The custodian keeps legal control and does not need a data transfer agreement for individual-level records. The sponsor gets consistent results because every site runs the same caller version, the same metabolizer mapping, and the same harmonized medication definitions. Ethics committees and data access committees can review a specific workflow and a specific set of permitted outputs, rather than an open-ended data release.

What changes for the sponsor

For a pharma sponsor, the practical difference is speed and reach. Negotiating individual-level transfers from several biobanks in different countries can take longer than the study itself. A federated approach replaces that with an approval to run a defined workflow and receive defined outputs, which data custodians can grant within their existing governance. It also widens the pool of eligible cohorts, because custodians that would never export genomes can still take part. The trade-off is discipline: the analysis plan, caller versions, and output list must be fixed before the study starts, which is good scientific practice anyway and aligns with the expectations of regulators reviewing pharmacogenomic evidence.

A governance and analysis framework

Step by step: a federated pharmacogenomics study

1. Pre-specify the question. Name the gene and drug pair, the outcome (exposure, efficacy, adverse event, dose requirement), and the populations of interest. Register the analysis plan before any data is touched.
2. Check coverage at each site. Confirm which pharmacogenes and variants each cohort’s sequencing or array platform captures, especially for structurally complex genes like CYP2D6. Run a count-only feasibility query first.
3. Harmonize medications and outcomes. Map prescribing and outcome data to the OMOP Common Data Model with shared concept sets, so “statin exposure” or “severe cutaneous reaction” means the same thing everywhere.
4. Distribute a locked workflow. Package the caller, CPIC or DPWG phenotype mapping, and statistical models in one container with version pinning.
5. Return aggregates and meta-analyze. Each site returns effect estimates, standard errors, and suppressed frequency tables by metabolizer group and ancestry. Combine them centrally with fixed or random-effects meta-analysis.
6. Report with provenance. Record which sites, workflow versions, and definitions produced each result, so regulators and reviewers can trace every number.

Real-world context

Public resources show how much of pharmacogenomics depends on shared, curated knowledge. PharmGKB curates evidence on gene and drug relationships, PharmVar maintains allele definitions, and CPIC guidelines are freely available. Large biobanks such as UK Biobank and the All of Us Research Program have released genomic data that researchers use to estimate pharmacogene allele frequencies in their participants, which helps predict how many patients a prescribing guideline would affect.

On the sponsor side, pharmaceutical companies increasingly want to reuse clinical and genomic data early in discovery and development without moving it. Boehringer Ingelheim works with Lifebit to accelerate clinical data reuse in early discovery, an example of the broader shift toward analyzing data where it sits. For pharmacogenomics, the same pattern applies: a sponsor designs the question and the workflow, and each data custodian keeps its records under its own control.

Common pitfalls

Inconsistent star-allele calling

Different callers and versions can assign different diplotypes to the same sample, especially for CYP2D6. Mixing results from different pipelines introduces artificial heterogeneity. Lock the caller and version across the network.

Assuming array data captures everything

Genotyping arrays may miss rare or population-specific alleles and structural variants. State coverage limits clearly, and treat “no variant detected” carefully rather than as “normal metabolizer.”

Medication data that is not harmonized

Local drug codes, free-text prescriptions, and missing dose information are the most common reasons multi-site pharmacogenomic analyses fail. Harmonization is the critical path, not an afterthought.

Small subgroups and disclosure

Poor metabolizer groups and rare adverse events produce small counts. Output rules must suppress or aggregate them, which should be planned for in the analysis design.

Treating return of results as an afterthought

Pharmacogenomic findings can be clinically actionable. Some programs have policies on whether and how actionable results are returned to participants or their clinicians. A research collaboration should know each custodian’s policy in advance, because it affects consent language and how outputs are handled.

Consent that does not cover commercial research

Some cohorts allow academic research only. Check terms per cohort and run the workflow only where the legal basis supports the collaboration.

What to do next

For sponsors, the first step is to identify which custodians hold the populations your label and development program need, and whether those data can ever be transferred. Usually they cannot, which makes the federated route the realistic one. Lifebit’s genomic data governance framework sets out the controls data custodians expect, the Boehringer Ingelheim collaboration shows how sponsors reuse data without moving it, and the federated Trusted Research Environment overview explains the platform that runs these workflows.

Frequently asked questions

What is pharmacogenomics research data?

It is data that links genetic variation, especially in genes affecting drug metabolism, transport, and immune response, to medication exposure, dosing, and outcomes. It typically combines genotypes or sequences with prescribing and clinical records.

Why is pharmacogenomics data hard to share?

It is genetic data, which is special category data under GDPR and subject to national genomic laws, and it is linked to detailed clinical records. Consent terms and data residency rules often prevent transfer, especially to commercial partners.

How does federated analysis work for pharmacogenomics?

A locked workflow is sent to each data custodian. Star-allele calling, metabolizer phenotype assignment, and statistical models run locally, and only reviewed aggregate results such as effect estimates return for meta-analysis.

What standards are used in pharmacogenomics research?

Common standards include PharmVar star-allele nomenclature, CPIC and DPWG guidelines for genotype to phenotype translation, and the OMOP Common Data Model with RxNorm or ATC codes for harmonizing medication and outcome data.

Why does ancestry diversity matter in pharmacogenomics?

Allele frequencies for important pharmacogenes vary widely between populations. HLA-B*15:02, linked to severe reactions to carbamazepine, is much more common in parts of Asia than in Europe. Studies limited to one ancestry can miss clinically important signals.

Can pharma sponsors analyze biobank data without receiving it?

Yes. In a federated Trusted Research Environment, the sponsor’s approved analysis runs inside each custodian’s environment and only aggregate, disclosure-checked results are released. The sponsor never receives individual-level genomes or records.